Male vs Female: Risk Factors for the Proportion of Responders of Tolterodine-Gender
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.809 | 0.795 | 0.822 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.864 | 0.854 | 0.874 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0556 | -0.0723 | -0.039 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.936 | 0.917 | 0.955 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.664 | 0.588 | 0.75 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Male than on Female | 18 | 13.8 | 25.7 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Male | Male participants who took tolterodine according to Japanese Package Insert. | 2,745 | 3,394 | OG000 | ClinicalTrials.gov |
| Group 2 | Female | Female participants who took tolterodine according to Japanese Package Insert. | 3,791 | 4,386 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Risk Factors for the Proportion of Responders of Tolterodine-Gender | ClinicalTrials.gov |
| Description | Number of participants with responders of tolterodine to determine whether male or female is significant risk factor. | ClinicalTrials.gov |
| Time frame | 12 week | ClinicalTrials.gov |
| Population | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) | ClinicalTrials.gov |
| NCT number | NCT01488578 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Overactive Bladder | ClinicalTrials.gov |
| Interventions | Tolterodine tartrate | ClinicalTrials.gov |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | ClinicalTrials.gov |
| Results first posted | 2012-06-14 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01488578?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.